


Therapeutic drug monitoring (TDM) with RIDASCREEN® & RIDA®QUICK

Therapeutic drug monitoring of TNF α blockers such as infliximab, adalimumab or golimumab and of the α 4 β 7 integrin-antagonist vedolizumab helps to optimize the treatment of patients and to improve therapy outcomes.

Key features of R-Biopharm's TDM portfolio:

- All TDM assays of R-Biopharm AG are validated by KU Leuven, Belgium
- ELISAs and rapid assays correspond due to identical monoclonal antibodies
- The assays have ready to use reagents
- RIDASCREEN® ELISAs are validated on automated ELISA readers such as DSX® and have breakable microwell plates
- The rapid point of care assays RIDA®QUICK IFX Monitoring and RIDA®QUICK ADM Monitoring allow the determination of trough level concentration of infliximab and its biosimilars and adalimumab, respectively within 20 minutes

RIDASCREEN® IFX Monitoring, Art. No. G09041



RIDA®QUICK IFX Monitoring, Art. No. GN3041



Products for therapeutic drug monitoring (TDM)

Infliximab lateral flow assay

Product	Description	Tests	Matrix	Art. No.
Lateral flow test and device				
RIDA®QUICK IFX Monitoring	Immunochromatographic lateral flow assay for the quantitative determination of infliximab (IFX) and its biosimilars	25	Serum/plasma	GN3041
RIDA®QUICK IFX Monitoring Control Set	Positive controls • accessory for GN3041			GP3041
New RIDA®QUICK ADM Monitoring	Immunochromatographic lateral flow assay for the quantitative determination of adalimumab (ADM)	25	Serum/plasma	GN3043
New RIDA®QUICK ADM Monitoring Control Set	Positive controls • accessory for GN3043			GP3043
RIDA®QUICK SCAN II - IVD SET	Lateral flow reader (CE-IVD) and 2D barcode scanner • for read out of GN3041 and GN3043			ZRQS2-KD-SET

ELISAs based on assays of KU Leuven, Belgium

Enzyme immunoassay				
RIDASCREEN® IFX Monitoring	Enzyme immunoassay for the quantitative determination of infliximab (IFX) and its biosimilars	96	Serum/plasma	G09041
RIDASCREEN® Anti-IFX Antibodies	Enzyme immunoassay for the quantitative determination of antibodies to infliximab (IFX) and its biosimilars	96	Serum/plasma	G09042
RIDASCREEN® ADM Monitoring	Enzyme immunoassay for the quantitative determination of adalimumab (ADM)	96	Serum/plasma	G09043
RIDASCREEN® Anti-ADM Antibodies	Enzyme immunoassay for the quantitative determination of antibodies to adalimumab (ADM)	96	Serum/plasma	G09044
RIDASCREEN® VDZ Monitoring	Enzyme immunoassay for the quantitative determination of vedolizumab (VDZ)	96	Serum/plasma	G09045
New RIDASCREEN® GLM Monitoring	Enzyme immunoassay for the quantitative determination of golimumab (GLM)	96	Serum/plasma	G09047

For further details and information visit our website www.r-biopharm.com, contact your local distributor or Clinical Sales International.

R-Biopharm contacts:

Clinical Sales International:
Phone: +49 (0) 61 51 - 81 02-0
Fax: +49 (0) 61 51 - 81 02-688
E-mail: clinical.sales@r-biopharm.de

Order Department:
Phone: +49 (0) 61 51 - 81 02-0
Fax: +49 (0) 61 51 - 81 02-20
E-mail: orders@r-biopharm.de